We aim to liberate patients from the burden of serious chronic disease

Our purpose

We have the courage to revolutionize medicine and create a first-in-class therapeutic category to liberate patients from chronic disease.

Our name

Our name is derived from sigilo – a Spanish word meaning stealth. Stealth is a key attribute of our Shielded Living Therapeutics™ platform, which we are using to harness the power of therapeutic cells without inducing an immune response.

Our aspiration

From cell function to functional cure to create a world without chronic disease.

Our team

Leadership
  • Leadership
  • Board of Directors
  • Founders
  • Scientific Advisory Board
David Aubuchon, MBA
David Aubuchon, MBA VP, Head of Finance +
Leadership

Mr. Aubuchon brings over 25 years of finance and accounting experience to the company. Before joining Sigilon he was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals (now Novelion Therapeutics). Mr. Aubuchon’s career in the life science industry began at Sepracor (now Sunovion) where his most recent position was as SVP and Chief Accounting Officer. At Sepracor he spent over a decade managing all accounting and government pricing functions and helped the company grow from a research organization to a fully-fledged commercial pharmaceutical business with six approved products, including LUNESTA and XOPENEX. Mr. Aubuchon has also held senior financial positions with other life sciences companies, including Ocata Therapeutics and Inspiration Biopharmaceuticals.

 

Mr. Aubuchon started his accounting career at Coopers & Lybrand (now PricewaterhouseCoopers) and earned a CPA in the state of Massachusetts. He holds a B.A. from the University of Massachusetts at Amherst and an M.B.A. from Babson College.

Hozefa Bandukwala, Ph.D.
Hozefa Bandukwala, Ph.D. Vice President, Platform Innovation +
Leadership

An immunologist by training, Hozefa Bandukwala, Ph.D., has pioneered the translation of advances in the emerging field of immunometabolism for novel drug development. Dr. Bandukwala has substantial industry experience in both big pharmaceutical and small biotechnology companies identifying novel targets for treatment of immunological diseases. Before Sigilon Therapeutics, Dr. Bandukwala served as Head of the Immunmetabolism Laboratory at Pfizer and Senior Director and Head of Discovery Biology at Rheos Medicines, where he led research efforts on manipulating immune cell metabolism for therapeutic applications in autoimmunity and immune-oncology.

 

Dr. Bandukwala earned a B.S. in biotechnology from the Indian Institute of Technology, Bombay and then pursued a Ph.D. in immunology from University of Chicago, where his research focused on the regulation of Th2 responses by Fc receptor signaling on dendritic cells. Dr. Bandukwala’s postdoctoral fellowship at Harvard University focused on epigenetic and metabolic regulation of T cell functions. His research has resulted in several high-profile publications.

Deya Corzo, M.D.
Deya Corzo, M.D. Chief Medical Officer +
Leadership

Deya Corzo, M.D., is an expert in biotechnology drug development, genetics and rare diseases with nearly two decades of experience leading clinical research initiatives.

 

Previously, Dr. Corzo served as Chief Medical Officer of Sojournix Inc., where she led a team responsible for IND/CTA regulatory filings in the USA and the UK, the execution of their first-in-human clinical trials in those geographies, and for building up the company’s clinical development group.

 

Dr. Corzo previously served as SVP of R&D and Therapeutic Area Head for liver-amenable gene therapies at uniQure. In that role she led efforts to develop a portfolio of preclinical AAV-based programs and oversaw a first-in-human clinical trial in hemophilia B in the EU for a gene therapy product that obtained Breakthrough Therapy and PRIME designation.

 

Dr. Corzo launched her biotechnology career at Genzyme where she led the medical team responsible for the global registration and subsequent approval of MyozymeTM and LumizymeTM, the only approved enzyme replacement therapies for Pompe disease.

 

Dr. Corzo is a faculty member of Harvard Medical School and a board-certified attending physician in Clinical Genetics at Boston Children’s Hospital.  She completed a residency in Pediatrics at Maimonides Medical Center in Brooklyn, NY, a clinical fellowship in Genetics at Boston Children’s Hospital and a research fellowship in Immunogenetics at the Dana-Farber Cancer Institute.  Dr. Corzo received her medical degree with a cum laude distinction from the Universidad Industrial de Santander in her native Colombia.

Susan Drapeau, Ph.D.
Susan Drapeau, Ph.D. Vice President, Head of Device and Delivery Engineering +
Leadership

Susan Drapeau, Ph.D. joins Sigilon Therapeutics with over 20 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Most recently, she served as the Senior Director of Business Development and Strategy at Vericel Corporation, where she evaluated new technologies and supported MACI and Epicel, two FDA approved autologous cellular therapies. Prior to Vericel, Dr. Drapeau spent 14 years at Medtronic Spine running part of the biologics product development organization as well as leading due diligence efforts in business development. While at Medtronic, her team launched five products, gained many 510(k) approvals, submitted several INDs and supported manufacturing, tech transfer, due diligence and intellectual property. Prior to Medtronic, Dr. Drapeau ran the bone product development team at Osiris Therapeutics, focusing on allogeneic cell therapies in combination with biomaterials. During her career Dr. Drapeau has worked in orthopedics, cardiac, burn, dental and pain therapies.

 

In addition to industry experience, Dr. Drapeau serves as an advocate for the biomedical field currently as a Director and previously as the Industry Chair of the American Institute of Medical and Biological Engineering. She also serves on the Advisory Board for UCSF Tissue Engineering Consortium Grant. Dr. Drapeau holds B.S. degrees in chemical engineering and chemistry from Purdue University and a Ph.D. in chemical engineering from Rice University. She is an inventor on 60 patents and a co-author of 90 journal articles, book chapters and presentations.

Melodie Henderson, J.D.
Melodie Henderson, J.D. VP, IP Counsel +
Leadership

Ms. Henderson is a registered U.S. patent attorney with over 20 years of legal, management and R&D experience with life science companies.

 

Prior to joining Sigilon, Ms. Henderson was the first in-house IP counsel at Minerva Neurosciences. Previously, Ms. Henderson served as a Legal Director for 11 years at Schering Pough/Merck, where her responsibilities included building and managing the patent portfolio for several pre-clinical and clinical biologics programs as well as five marketed products. Ms. Henderson’s first in-house legal role was at Genaissance Pharmaceuticals, where she established the IP function and managed a team of patent professionals. Before going in-house, Ms. Henderson began her legal career as an associate attorney at two IP boutique law firms.

 

Ms. Henderson holds a B.A. degree in biochemistry from the University of Kansas, an M.S. degree in biochemistry from St. Louis University and a J.D. from the University of Connecticut

Olivia G. Kelly, Ph.D.
Olivia G. Kelly, Ph.D. VP, Head of Islet Cell Therapy Research +
Leadership

Dr. Olivia G. Kelly has over 13 years of experience in the biotechnology industry developing cell therapies. Prior to joining Sigilon, Dr. Kelly served as the Senior Director of Cell Biology at ViaCyte, a clinical stage company focused on developing stem cell-derived therapies for diabetes, where she led efforts in stem cell differentiation, assay development, quality control and tumorigenicity studies which supported multiple IND/CTA filings and achieved multiple research grant and licensing milestones. Dr. Kelly has coauthored a number of high-profile journal publications and is a co-inventor on multiple patents.

 

Dr. Kelly earned a B.S. in Molecular Biology from the University of Texas at Austin and then pursued a Ph.D. in Biochemistry and Molecular Biology from Harvard University, where her research focused on molecular mechanisms of early embryonic patterning and pancreas development. Dr. Kelly’s postdoctoral fellowships at the University of California at Berkeley/San Francisco and Baylor College of Medicine focused on signaling mechanisms that regulate the development of various tissues and stem cell differentiation.

Matthew Kowalsky
Matthew Kowalsky Senior Vice President, General Counsel +
Leadership

Matthew Kowalsky brings a wide range of legal experience to his leadership role at Sigilon. Most recently, he was Vice President of Legal and Corporate Secretary at Proteon Therapeutics, a Nasdaq-listed biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals. Before joining Proteon, he was Senior Corporate Counsel at Sanofi Genzyme where he supported business development activities, alliances and marketed products for rare diseases and served as a member of the Rare Operating Leadership team. Prior to Sanofi Genzyme, Mr. Kowalsky was Associate General Counsel at Cubist Pharmaceuticals, which was acquired by Merck in 2015. He has also held similar roles at ARIAD Pharmaceuticals and Lantheus Medical Imaging (formerly Bristol-Myers Squibb Medical Imaging).

 

Mr. Kowalsky started his career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from University of Notre Dame and a J.D. from Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.

David E. Moller, M.D.
David E. Moller, M.D. Chief Scientific Officer +
Leadership

Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies. Previously, Dr. Moller was Vice President of Business Development – Emerging Technology and Innovation at Eli Lilly, evaluating applications of breakthrough biology across multiple therapeutic areas. As Vice President of Endocrine and Cardiovascular Research and Clinical Investigation at Eli Lilly, Dr. Moller was responsible for discovery and early development in diverse therapeutic areas – his team contributed to several Lilly pipeline additions including dulaglutide (Trulicity). Prior to joining Eli Lilly, Dr. Moller led global discovery efforts in metabolic disorders as Vice President, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia). Before moving to industry, Dr. Moller was on the faculty of Harvard Medical School. He completed a residency in Internal Medicine at George Washington University, received his medical degree from the University of Cincinnati and earned a B.S. from Brown University.

David Peritt, Ph.D.
David Peritt, Ph.D. Chief Technology Officer +
Leadership

A cellular immunologist by training, Dr. Peritt has substantial industry experience in biologics and cell therapy R&D. Throughout his 30-year career working in academic, industrial, governmental, and military institutes, Dr. Peritt has developed life-saving therapies for hematological malignancies and autoimmune diseases. Before Sigilon, Dr. Peritt held various leadership positions including, Program Lead for Cell and Gene Therapy at Pfizer, Head of Biosimilars Biology at Hospira, and Scientific Lead for Strategic Investment in Cell Therapy for Hospira. He has led research efforts at several divisions of Johnson & Johnson including Centocor and Therakos and worked in governmental agencies such as the USDA, Walter Reed Army Medical Center, and the Sharrett Cancer Institute.

 

Dr. Peritt has numerous patents and publications to his name, as well as several therapies on the market that improve the lives of patients. He received his Ph.D. and post-doctoral training in immunology from the University of Pennsylvania and the Wistar Institute.

Glenn Reicin, MBA
Glenn Reicin, MBA Chief Financial Officer +
Leadership

Glenn Reicin brings over 30 years of healthcare experience with a broad and deep background in investment banking, private equity and venture capital to his position as the Chief Financial Officer of Sigilon. In addition to supervising Sigilon’s financial team, Mr. Reicin will be responsible for advising the CEO, other senior executives, the Board of Directors, investors, and other stakeholders on Sigilon’s plans to optimize return and minimize risk in the ever-changing biotech industry.

 

Mr. Reicin has a strong track record in private equity.  He served as President and Founder of Greyrock Biomedical Advisors, advising companies in the medical space on asset purchases, direct loans and passive royalties. Prior to Greyrock, Mr. Reicin was a Managing Director at Skyline Ventures, a venture firm focused on healthcare therapeutics. On the public investing side, Mr. Reicin was a Managing Director at Morgan Stanley, heading their Healthcare Equity Research. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the #1 spot.

 

Mr. Reicin holds a B.A. in economics from Brandeis University and an MBA from Harvard Business School. An avid runner, Glenn has completed eight marathons and is passionate about minor league baseball.

Martha Rook, Ph.D.
Martha Rook, Ph.D. SVP, Head of Manufacturing +
Leadership

Dr. Rook has over 20 years of academic and industry experience in molecular biology, diagnostics development and cell and gene therapy manufacturing.

 

Prior to joining Sigilon, Dr. Rook was VP and Head of the Gene Editing & Novel Modalities Business of MilliporeSigma. There she led a team developing and providing tools and services for cell and gene therapies from discovery to manufacturing. Those tools included genome editing research tools, cell model systems and a platform of scalable, disposable production solutions for the manufacture of cell & gene-based therapies as well as contract manufacturing services for viral vector production. Dr. Rook also previously held a variety of senior roles at MilliporeSigma including Head of Novel Therapies, Director of Stem Cell Bioprocessing and Head of Upstream and Sensor Technologies. Prior to joining MilliporeSigma, Dr. Rook worked in the clinical diagnostics field at Quest Diagnostics and Variagenics.

 

Dr. Rook received her Ph.D. in biochemistry from MIT and holds a B.S. in chemistry from Texas A&M University. She pursued post-doctoral studies in neuroscience as a Lefler Fellow at Harvard Medical School’s Center for Neurologic Diseases.

Vanya Sagar, MPA
Vanya Sagar, MPA VP, Head of Human Resources +
Leadership

Ms. Sagar joined Sigilon as Vice President, Head of Human Resources with a decade and a half of experience in global HR and operations. Ms. Sagar is passionate about attracting, retaining and developing exceptional, diverse talent. Throughout her career, she has held roles of increasing responsibility both in industry and academia, bringing value from strategic and tactical perspectives alike. Most recently, Ms. Sagar served as the HR Business Partner for the Research and Early Development organization at Biogen and prior to that, for the global Finance organization. Prior to her Business Partner roles, Ms. Sagar served as the Talent Acquisition Sourcing Leader for Biogen’s R&D, Pharmaceutical Operations & Technology, and G&A functions. Before her time at Biogen, she spent several years at Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School in various roles in the department of Neurology. Her most recent roles include Administrative Director of Inpatient Clinical Operations and Administrative Director for Education, with progressive responsibilities spanning resident and fellow recruitment, on-boarding, training and development, performance management, and program and project administration, among others. During her time in academia, Ms. Sagar was an invited member of the Education subcommittee at the American Academy of Neurology. Ms. Sagar holds a Bachelor’s degree in Counseling from Dominion College and a Master’s of Public Administration from Suffolk University.

Devyn Smith, Ph.D.
Devyn Smith, Ph.D. Chief Strategy Officer & Head of Operations +
Leadership

Dr. Devyn Smith is Sigilon Therapeutics’ Chief Strategy Officer and Head of Operations. In this role, Dr. Smith is tasked with building the strategy and executing on the operational elements of our portfolio of potential new medicines.

 

Before joining Sigilon Therapeutics, Dr. Smith was part of Pfizer’s Medicinal Sciences Division of R&D, where he was Head of Business Operations & Strategy. His responsibilities in this position included oversight of both the day-to-day business operations of the division and the development of implementable strategies. Dr. Smith also held several other high-level positions at Pfizer including Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D and Chief Operating Officer of Pfizer’s Neusentis Research Unit in the UK. He also supported the Pharmatherapeutics Global Clinical Research Organization as Chief Operating Officer. Before his time at Pfizer, Dr. Smith was a principal for management consulting firm, The Frankel Group. During this period, his clients ranged from large pharmaceutical to small biotech companies. Throughout his career, Regenerative Medicine has been a strong area of focus of Dr. Smith’s research. He has published multiple papers and delivered over 50 invited conference presentations at cell therapy meetings related to the subject.

 

Dr. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University.

James D. Watson, MBA
James D. Watson, MBA Chief Business Officer & President, Islet Cell Therapy +
Leadership

Mr. Watson has over 25 years of experience working in the biopharmaceutical industry. Most recently, he was Chief Business Officer at Alvine Pharmaceuticals where he and his team put in place an option for acquisition by AbbVie and managed the Alvine/AbbVie alliance for over 2 years. Before his time at Alvine, Mr. Watson was Managing Director and Head of Private Equity at Burrill & Company. He also spent nearly 5 years as CEO of Burrill’s Merchant Banking Group, a role in which he advised numerous biopharmaceutical clients on strategic transactions. Prior to Burrill, Mr. Watson was SVP of Corporate Development and Marketing at Incyte and General Manager at Chemdex. He also served as Head of the San Francisco office of The Wilkerson Group. He began his career with Eli Lilly holding a variety of sales, marketing, and new product planning positions.

 

Mr. Watson holds a B.A. in Economics from Portsmouth University in England and a Fulbright Scholarship and M.B.A. from Indiana University.

Rogerio Vivaldi, M.D., MBA
Rogerio Vivaldi, M.D., MBA President, Chief Executive Officer +
Leadership, Board of Directors

Rogerio Vivaldi, M.D., M.B.A. is the President and Chief Executive Officer of Sigilon Therapeutics. During his more than 25 years as a physician and an industry executive, Dr. Vivaldi has built a reputation as a devoted advocate for patients, particularly those with chronic diseases.

 

Most recently, he served as Executive Vice President and Chief Global Therapeutic Operations Officer at Bioverativ, which was acquired in 2018 by Sanofi for $11.6 billion. Prior to Bioverativ, Dr. Vivaldi was Chief Commercial Officer at Spark Therapeutics, where he worked to commercialize the company’s gene therapeutics. He also managed Spark’s Medical Affairs and Patient Advocacy groups.

 

Prior to Spark, Dr. Vivaldi co-founded and served as President and CEO of Minerva Neurosciences, a clinical-stage company developing products for patients with neuropsychiatric diseases. Before co-founding Minerva, he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his almost 20-year tenure at Genzyme.

 

Dr. Vivaldi was the first physician in Latin America to manage Enzyme Replacement Therapy (ERT) for a patient with Gaucher Disease back in 1991. He ran an endocrinology clinic primarily focused on type 1 diabetes for 18 years and is himself a person with type 1 diabetes.

 

Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro (UNIRIO). He completed a residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. He also holds an MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ).

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Professor of Chemical Engineering at the Massachusetts Institute of Technology and pioneer in the development of smart biomaterials, Dr. Anderson also holds appointments in the Institute for Medical Engineering and Science at MIT as well as in the Harvard-MIT Division of Health Science and Technology. His work has resulted in the publication of over 300 papers, patents and patent applications and has led to a number of products that have been commercialized or are in clinical development. Dr. Anderson received a B.A. from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis.

Doug Cole, M.D.
Doug Cole, M.D. Chairman +
Board of Directors

A managing partner at Flagship Pioneering, Dr. Cole previously led a multidisciplinary program at Vertex Pharmaceuticals that conducted development in tissue protection and repair, oversaw an international research collaboration and was responsible for identifying strategic market and technology opportunities. He has formerly served on the Boards of Directors of Avedro, AVEO Pharmaceuticals, CombinatoRx, Concert, CGI, Moderna, Morphotek, Receptos, Resolvyx, Selecta, Seventh Sense and Tetraphase. Dr. Cole is a member of the Board of Directors of the Spinal Muscular Atrophy Foundation. Dr. Cole holds an A.B. from Dartmouth and an M.D. from the University of Pennsylvania School of Medicine.

John Cox, MBA
John Cox, MBA +
Board of Directors

Mr. Cox brings to Sigilon over 25 years of experience in biopharmaceuticals. He is currently the Executive Chairman of Torque, and was formerly the Chief Executive Officer of Bioverativ, which he built, grew, and led to a successful acquisition by Sanofi. Previously, Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen, where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply. Prior to that he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen, in which capacity he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company’s biosimilar business, including its successful commercialization in Europe. Mr. Cox holds an MBA from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.

Jeffrey Flier, M.D.
Jeffrey Flier, M.D. +
Board of Directors

A highly distinguished endocrinologist, researcher and academic, Dr. Flier is one of the country’s foremost investigators in the areas of obesity and diabetes. From 2007 to 2016, Dr. Flier was the Dean of the Faculty of Medicine at Harvard University. Dr. Flier is now the Harvard University Distinguished Service Professor and the George Higginson Professor of Physiology and Medicine at Harvard Medical School. He previously served as Harvard Medical School Faculty Dean for Academic Programs. Dr. Flier’s honors also include the Eli Lilly Award of the American Diabetes Association, the Berson Lecture of the American Physiological Society and honorary doctorates from the University of Athens and the University of Edinburgh. He was the recipient of the Edwin B. Astwood Lecture Award from the Endocrine Society and has received the Banting Medal, the highest scientific honor awarded by the American Diabetes Association. Dr. Flier received a B.S. from the City College of New York and an M.D. from Mount Sinai School of Medicine, where he graduated with the Elster Award for Highest Academic Standing.

Jim Gilbert, MBA
Jim Gilbert, MBA +
Board of Directors

Mr. Gilbert is a Senior Partner at Flagship Pioneering and serves as the Director of Rubius Therapeutics. Mr. Gilbert began his career at Bain & Company, where he worked for over 24 years. At Bain, Mr. Gilbert served as the Managing Director of the Global Healthcare Practice. He also served as Chairman of Bain’s management committee. Mr. Gilbert graduated from Cornell University School of Engineering where he earned a B.S. and received an M.B.A. from Harvard Business School.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Dr. Langer has been a leading expert on controlled release technology for over 40 years and is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has received the Queen Elizabeth Prize for Engineering, the Charles Stark Draper Prize, the Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal, the Gairdner Prize, the Kyoto Prize, the 2014 Breakthrough Prize in Life Sciences and the Lemelson-MIT Prize. He is one of four living individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. Dr. Langer has been the founder or a founding member of over 25 successful biotechnology companies.

Stephen Oesterle, M.D.
Stephen Oesterle, M.D. +
Board of Directors

Dr. Oesterle was Senior Vice President for Medicine and Technology at Medtronic, where he was responsible for scientific research, formation of technological strategies and development of strong cooperative relationships with the world’s medical communities. During his 14 years on the executive committee of Medtronic, he was also a member of the operating, strategy and investment committees. Dr. Oesterle has served on more than 20 boards of emerging companies in technology and healthcare. Prior to joining Medtronic in 2002, Dr. Oesterle served as Associate Professor of Medicine at the Harvard University Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital. Dr. Oesterle graduated summa cum laude from Harvard University and received his M.D. from the Yale School of Medicine.

Robert Ruffolo, Jr., Ph.D.
Robert Ruffolo, Jr., Ph.D. +
Board of Directors

Dr. Ruffolo has been responsible for the discovery and development of several marketed products over the course of his career in the pharmaceutical industry. He is the former President of Research and Development for Wyeth Pharmaceuticals, managing a research and development organization of 9,000 scientists with an annual budget in excess of $3 billion. Before joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he was Senior Vice President and Director of Biological Sciences, Worldwide. Dr. Ruffolo received both a Ph.D. in pharmacology and a B.S. from The Ohio State University. Dr. Ruffolo has received numerous awards including the 2008 Scrip Lifetime Achievement Award and the 2008 Discoverer’s Award for the discovery and development of Coreg (carvedilol) for the treatment of congestive heart failure.

Eric Shaff, MBA
Eric Shaff, MBA +
Board of Directors

Eric Shaff is President and Chief Executive Officer of Seres Therapeutics, a role that follows a series of leadership positions in corporate finance in the biopharmaceutical industry. Prior to Seres, Mr. Shaff worked at Momenta Pharmaceuticals and Genzyme Corporation, where he served as global head of finance of Genzyme’s Rare Genetic Disease Division in addition to roles in corporate development and corporate Finance. Mr. Shaff has also worked in corporate finance at Pfizer and in investment banking with Broadview International (now Jefferies Broadview). Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.

Rogerio Vivaldi, M.D., MBA
Rogerio Vivaldi, M.D., MBA President, Chief Executive Officer +
Leadership, Board of Directors

Rogerio Vivaldi, M.D., M.B.A. is the President and Chief Executive Officer of Sigilon Therapeutics. During his more than 25 years as a physician and an industry executive, Dr. Vivaldi has built a reputation as a devoted advocate for patients, particularly those with chronic diseases.

 

Most recently, he served as Executive Vice President and Chief Global Therapeutic Operations Officer at Bioverativ, which was acquired in 2018 by Sanofi for $11.6 billion. Prior to Bioverativ, Dr. Vivaldi was Chief Commercial Officer at Spark Therapeutics, where he worked to commercialize the company’s gene therapeutics. He also managed Spark’s Medical Affairs and Patient Advocacy groups.

 

Prior to Spark, Dr. Vivaldi co-founded and served as President and CEO of Minerva Neurosciences, a clinical-stage company developing products for patients with neuropsychiatric diseases. Before co-founding Minerva, he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his almost 20-year tenure at Genzyme.

 

Dr. Vivaldi was the first physician in Latin America to manage Enzyme Replacement Therapy (ERT) for a patient with Gaucher Disease back in 1991. He ran an endocrinology clinic primarily focused on type 1 diabetes for 18 years and is himself a person with type 1 diabetes.

 

Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro (UNIRIO). He completed a residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. He also holds an MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ).

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Professor of Chemical Engineering at the Massachusetts Institute of Technology and pioneer in the development of smart biomaterials, Dr. Anderson also holds appointments in the Institute for Medical Engineering and Science at MIT as well as in the Harvard-MIT Division of Health Science and Technology. His work has resulted in the publication of over 300 papers, patents and patent applications and has led to a number of products that have been commercialized or are in clinical development. Dr. Anderson received a B.A. from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Dr. Langer has been a leading expert on controlled release technology for over 40 years and is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has received the Queen Elizabeth Prize for Engineering, the Charles Stark Draper Prize, the Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal, the Gairdner Prize, the Kyoto Prize, the 2014 Breakthrough Prize in Life Sciences and the Lemelson-MIT Prize. He is one of four living individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. Dr. Langer has been the founder or a founding member of over 25 successful biotechnology companies.

José Oberholzer, M.D.
José Oberholzer, M.D. +
Founders

Dr. José Oberholzer is a scientific founder at Sigilon. He is a physician-scientist with a long track record in cell therapy.
Dr. Oberholzer, brings a wealth of highly valuable islet encapsulation expertise to Sigilon. He is a researcher, surgeon and the director of the Charles O. Strickler Transplant Center at the University of Virginia. Previous to that he was a Professor of Surgery, Endocrinology and Diabetes, Bioengineering, and Chief of the Division of Transplantation at the University of Illinois at Chicago (UIC).

 

Dr. Oberholzer graduated from the University of Zurich Medical School in Switzerland and obtained a master’s in health care management from Harvard University. He completed his surgical training at the University of Geneva (Switzerland), as well as at the University of Alberta in Edmonton (Canada), where he completed a fellowship in hepatobiliary and pancreatic surgery and transplantation. He was the Head of the Islet Transplant Program at the University of Geneva and the GRAGIL islet consortium from 1998 to 2002, completing a significant number of islet transplants. He has been heading UIC’s islet program since 2003.

Arturo Vegas, Ph.D.
Arturo Vegas, Ph.D. +
Founders

Scientific Founder Arturo Vegas, Ph.D., provided fundamental contributions to the development of new materials for cell encapsulation and cell-based therapies as a post-doctoral fellow in the MIT laboratories of Robert Langer and Daniel G. Anderson. He is currently the Peter Paul Career Development Professor at Boston University. Appointed in the Department of Chemistry, Dr. Vegas has an affiliation with the Department of Biomedical Engineering and is a core faculty member of both the Boston University Center for Molecular Discovery as well as the Boston University Nanotechnology Innovation Center. Dr. Vegas received his B.A. from Cornell University and a Ph.D. in Chemistry from Harvard University. His work has led to 10 patents both issued and pending. He was recently awarded a New Innovator Type 1 Diabetes Pathfinder Award by the NIH.

Omid Veiseh, Ph.D.
Omid Veiseh, Ph.D. +
Founders

Scientific Founder, Omid Veiseh, Ph.D., has over a decade of experience developing biotechnologies for clinical application. The transformative research discoveries he made as a postdoctoral research fellow helped catalyze the launch of Sigilon. Through grants from the Juvenile Diabetes Research Foundation and the Department of Defense, Dr. Veiseh worked to develop a bioartificial pancreas for the treatment of patients afflicted with type 1 diabetes. Dr. Veiseh developed a high-throughput pipeline for the synthesis and evaluation of material formulations that are able to resist foreign body reactions. These formulations were used to develop novel biomaterials for enhanced biocompatibility. The results lay the groundwork for encapsulated transplanted cells for delivery of biotherapeutics. In 2017, he will join the faculty at Rice University as an Assistant Professor of Bioengineering. Dr. Veiseh holds a Ph.D. from the University of Washington. He has authored or co-authored more than 50 peer-reviewed publications and is an inventor on 20 pending or awarded patents.

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Professor of Chemical Engineering at the Massachusetts Institute of Technology and pioneer in the development of smart biomaterials, Dr. Anderson also holds appointments in the Institute for Medical Engineering and Science at MIT as well as in the Harvard-MIT Division of Health Science and Technology. His work has resulted in the publication of over 300 papers, patents and patent applications and has led to a number of products that have been commercialized or are in clinical development. Dr. Anderson received a B.A. from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Dr. Langer has been a leading expert on controlled release technology for over 40 years and is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has received the Queen Elizabeth Prize for Engineering, the Charles Stark Draper Prize, the Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal, the Gairdner Prize, the Kyoto Prize, the 2014 Breakthrough Prize in Life Sciences and the Lemelson-MIT Prize. He is one of four living individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. Dr. Langer has been the founder or a founding member of over 25 successful biotechnology companies.

Constance Cepko, Ph.D.
Constance Cepko, Ph.D. +
Scientific Advisory Board

Dr. Cepko is Professor of Genetics and Neuroscience and Co-Director of the Leder Human Biology and Translational Medicine Program at Harvard Medical School. Her laboratory addresses questions regarding mechanisms of cell fate determination and has been developing gene therapy to address genetic forms of blindness. Dr. Cepko serves on the Scientific Advisory Boards of Permeon Biologics, Advanced Cell Technology and GenSight Biologics. Dr. Cepko is a member of American Academy of Arts and Sciences and member of the National Academy of Sciences.

Mark Kay, M.D., Ph.D.
Mark Kay, M.D., Ph.D. +
Scientific Advisory Board

Dr. Kay is the Head of the Division of Human Gene Therapy and the Associate Chair of Research in Pediatrics at Stanford University. Dr. Kay’s research addresses the scientific principles of gene and nucleic acid transfer for the treatment of genetic and acquired diseases. He is a scientific founder of Voyager Therapeutics and LogicBio Therapeutics. Dr. Kay serves on the board of the Oligonucleotide Therapeutics Society and is founding member and previous president of the American Society for Gene Therapy. Dr. Kay was honored as 2013 Researcher of the Year by the National Hemophilia Foundation and is the recipient of the American Society for Gene and Cell Therapy 2013 Outstanding Investigator Award. Dr. Kay has published over 250 peer-reviewed articles.